|
|
||||||||
1Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; 2Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, and 3Chemical Preparations Research, Alcon Research, Ltd., Fort Worth, Texas
Submitted 11 September 2007 ; accepted in final form 16 January 2008
| ABSTRACT |
|---|
|
|
|---|
endothelium-derived hyperpolarizing factor; smooth muscle cells; potassium channels; arachidonic acid
Although 11,12,15-THETA has been identified as the vasodilatory 15-LO metabolite produced by rabbit endothelium, the stereochemical configuration of this THETA is not known. The rabbit endothelium contains 15-LO and produces the S isomer of 15-hydroxyeicosatetraenoic acid at 96% optical purity (21, 26). Thus the 15-hydroxy group has the S configuration. The amount of 11,12,15-THETA produced by the aorta is not adequate for stereochemical determination of the 11- and 12-hydroxyl groups. As a result, we have chemically synthesized eight stereoisomers of 11,12,15(S)-THETA and compared their biological activities and chromatographic migrations with activity and migration of the biologically produced 11,12,15-THETA. These studies indicate that only 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA comigrated with the biological THETA in several chromatographic systems, relaxes the rabbit aorta and activates K+ channels. These findings strongly suggest that the EDHF produced by the rabbit aorta is 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA.
| METHODS |
|---|
|
|
|---|
13,14-olefin can have the cis (Z) or trans (E) configuration. These permutations give rise to eight stereoisomers of 11,12,15(S)-THETA, i.e., four with a cis-
13,14-olefin [13(Z) series] and four with a trans-
13,14-olefin [13(E) series]. These eight stereoisomers of 11,12,15(S)-THETA were prepared by total asymmetric synthesis as previously described (6, 8) and compared chromatographically and via bioassay with natural material. The structures of these eight stereoisomers are shown in Fig. 1.
|
Aortas were isolated from 1- to 2-mo-old New Zealand White rabbits and cleaned of adhering connective tissue and fat (3, 22, 23). The vessels were rinsed in HEPES buffer [in mM: 10 HEPES, 150 NaCl, 5 KCl, 2 CaCl2,1 MgCl2, and 6 mM glucose (pH 7.4)] and cut into 3-mm-long rings. Vessels were incubated for 10 min at 37°C in HEPES buffer containing 10–5 M indomethacin and 0.05 µCi of 5 x 10–5 M [14C]AA. A-23187 (2 x 10–5 M) was added, and the vessels were incubated for an additional 5 min. The reaction was stopped by addition of ethanol to a final concentration of 15%, and the HEPES buffer was collected, acidified (pH <3.5) with glacial acetic acid, and extracted on octadecylsilica solid-phase extraction columns as previously described (22, 23). The extracted metabolites were evaporated to dryness under a stream of nitrogen and stored at –40°C until analysis by HPLC.
Purification of aortic 11,12,15-THETA by HPLC. The biologically produced [14C]11,12,15-THETA was isolated by HPLC, and its migration time in three HPLC systems was compared with that of the synthetic 11,12,15-THETA stereoisomers (3, 23, 24). Elution times of the biological [14C]11,12,15-THETA were determined by measurement of the radioactivity in the column eluate, whereas elution time of the synthetic 11,12,15-THETA stereoisomers was determined by UV absorbance at 205 nm. The extracted aortic metabolites of [14C]AA were first resolved into their components by reverse-phase (RP) HPLC using a Nucleosil C18 column (5 µm, 4.6 x 250 mm) and solvent system I (23). Solvent A was water, and solvent B was acetonitrile containing 0.1% glacial acetic acid. The program was a 40-min linear gradient from 50% solvent B in solvent A to 100% solvent B. Flow rate was 1 ml/min. Column eluate was monitored for absorbance at 205 nm and collected in 0.2-ml fractions by a fraction collector. An aliquot of each fraction was removed, and radioactivity was determined by liquid scintillation spectrometry. Fractions corresponding to the THETAs (fractions 27–35, 5–7.5 min) were collected, acidified, and extracted with 50:50 cyclohexane-ethyl acetate. The solvent was removed under a stream of nitrogen, and the residue was redissolved in the HPLC mobile phase. The THETA fraction was rechromatographed on RP-HPLC using the same column with solvent system II (23). In solvent system II, solvent A was water containing 0.1% glacial acetic acid, and solvent B was acetonitrile. The program consisted of a 5-min isocratic phase with 35% solvent B in solvent A followed by a 35-min linear gradient to 85% solvent B. Flow rate was 1 ml/min. The column eluate was monitored for absorbance at 205 nm and collected in 0.2-ml aliquots, and radioactivity was determined as described above. Fractions containing the THETAs (15.0–17.6 min, fractions 75–88) were collected, acidified, and extracted with 50:50 cyclohexane-ethyl acetate. The THETA fraction was further purified by normal-phase (NP) HPLC using a Nucleosil silica column (5 µm, 4.6 x 250 mm) (3, 24). Solvent system III consisted of an isocratic separation for which 95.9:4:0.1 hexane-isopropranol-glacial acetic acid was used at a flow rate of 1 ml/min. The column eluate was monitored for absorbance at 205 nm and collected in 0.5-ml fractions, and the radioactivity was determined as described above. The radioactive peak containing 11,12,15-THETA (fractions 93–99, 46.5–49.5 min) was collected, dried under a stream of nitrogen, derivatized, and analyzed by gas chromatography (GS)-mass spectrometry (MS; see below). The GC-MS analysis confirmed that these fractions contained 11,12,15-THETA with major ions [mass-to-charge ratio (m/z)] of 569 (M-15, loss of CH3), 405 [M-179, loss of (CH3)3SiOH and (CH3)3SiO+], 301 (M-283), 283 {M-301, [(CH3)3SiO]-CH-(CH2-CH=CH)2-(CH2)3-COOCH3}, and 173 {M-411, [(CH3)3SiO]-(CH2)4-CH3}. The relative intensity of m/z 283 vs. 173 indicates the presence of 11,12,15-THETA (23). Mass spectra with the same major ions were obtained with synthetic 11,12,15-THETA standards.
GC-MS analysis of aortic and synthetic 11,12,15-THETAs. The pooled 11,12,15-THETA fractions isolated from solvent system III were evaporated to dryness using a nitrogen stream and derivatized for GC-MS as previously described (23). The biological sample and synthetic 11,12,15-THETA standards were dissolved in 120 µl of acetonitrile and then treated with ethereal diazomethane for 6 min at 0°C to form the methyl ester. The reacted sample was evaporated to dryness under nitrogen, and the hydroxyl groups were converted to the trimethylsilyl (TMS) ethers by 60 min of incubation with 15 µl of bis-TMS-trifluoroacetamide at 37°C. GC-MS was performed with a Hewlett-Packard mass spectrometer (model 5989A) coupled with a gas chromatograph (model 5890, series 2). Chemical ionization of the samples was performed at 65–70 eV with methane as the reagent gas. Ions were measured in the positive-ion mode as total ion current. The derivatized biological 11,12,15-THETA and synthetic THETA standards were resolved using a 14-m capillary DB-5 column with a linear gradient from 100 to 300°C. Migration times of the 11,12,15-THETA standards were compared with that of the biological 11,12,15-THETA.
Vascular reactivity of 11,12,15-THETA isomers. Thoracic aorta was obtained from 1- to 2-mo-old New Zealand White rabbits and placed in Krebs bicarbonate buffer (in mM: 118 NaCl, 4 KCl, 3.3 CaCl2, 24 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, and 11 glucose) as previously described (3, 20, 22). The tissue was carefully cleaned of adhering fat and connective tissue and cut into 3-mm-long rings, with care taken not to damage the endothelium. Aortic rings were suspended in 6-ml tissue baths containing Krebs bicarbonate buffer maintained at 37°C and continuously bubbled with 95% O2-5% CO2. Isometric tension was measured with force-displacement transducers (model FT-03C, Grass) and amplifiers (model ETH-400, ADInstruments) and recorded on a MacIntosh computer using MacLab software. Resting tension was adjusted to its length-tension maximum of 2 g, and vessels were allowed to equilibrate for 1 h. Contractions were produced by increasing the KCl concentration of the Krebs buffer to 40 mM. After the vessels reached peak contraction, the tissue baths were rinsed, and vessels returned to resting tension. Once the aortic rings had reproducible, stable responses to KCl, the tissue was contracted with 10–8–10–7 M phenylephrine to 50–75% maximal KCl contraction. The 11,12,15(S)-THETA isomers were dissolved in ethanol and tested for activity. In other experiments, the vessels were pretreated with 100 nM apamin for 10 min before preconstriction with phenylephrine and addition of the 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA standard. Similar amounts of phenylephrine were used to contract the control and apamin-treated arterial rings. Relaxations are expressed as percent relaxation relative to phenylephrine preconstruction, with 100% representing basal tension.
K+ channel activity of 11,12,15-THETA isomers. Aortic smooth muscle cells were enzymatically dispersed using published methods (12). Whole cell recordings of K+ currents were obtained in freshly isolated aortic smooth muscle cells using an amplifier (Axopatch 200B, Axon Instruments), pClamp 8 software (Axon Instruments), and standard methods, as previously described (12). Briefly, macroscopic K+ currents were generated by progressive 10-mV depolarizing steps (500-ms duration, 5-s intervals) from a constant holding potential of –60 to +60 mV. Currents were sampled at 3 kHz and filtered at 1 kHz. Trials were performed in triplicate and averaged to estimate K+ current density. Membrane capacitance of each cell was estimated by integration of the capacitive current generated by a 10-mV hyperpolarizing pulse after electronic cancellation of pipette-patch capacitance. Indomethacin (10–5 M) was present in all perfusate solutions. After control vehicle currents were recorded, increasing concentrations (10–100 µM) of 11(R),12(S),15(S),5(Z),8(Z),13(E)- or 11(R),12(R),15(S),5(Z),8(Z),13(E)-THETA were added, and currents were obtained. In a subset of experiments, cells were treated with 10–7 M apamin before addition of 11(R),12(S),15(S)-THETA. Results are shown as percent current density, with 100% equal to current density measured at +60 mV under control (vehicle) conditions.
Data analysis. Relaxation and patch-clamp results are presented as means ± SE. Significance of difference between mean values was evaluated by two-way ANOVA followed by the Student-Newman-Keuls multiple comparison test. P < 0.05 was considered statistically significant.
| RESULTS |
|---|
|
|
|---|
|
13,14-olefin [13(Z)] relaxed or contracted the rabbit aorta at 10–7–10–4 M (Fig. 3). Of the four isomers with the trans-
13,14-olefin [13(E)], 11(R),12(S),15(S)-THETA relaxed the rabbit aorta in a concentration-related manner, with significant relaxations at 10–6 M (Fig. 3A). Maximal relaxations to this isomer were 69 ± 5% (P < 0.01). These relaxations were inhibited by pretreatment with the SKCa channel blocker apamin (100 nM). In comparison, 10–4 M 11(S),12(R),15(S)-THETA relaxed the aorta by only 22% (Fig. 3C). At 10–4 M, 11(R),12(R),15(S)-THETA contracted the aorta (Fig. 3B), whereas 11(S),12(S),15(S)-THETA was without effect (Fig. 3D). Ethanol vehicle used with the THETA standards was without effect (Fig. 3A).
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Very little is known about the mechanism of action of 11,12,15-THETA because of the lack of availability of the eicosanoid. Biosynthetic 11,12,15-THETA, produced by the rabbit aorta, relaxed precontracted rabbit aorta, hyperpolarized vascular smooth muscle, and activated SKCa channels in smooth muscle cells (3, 12). The exact structure of the biologically active 11,12,15-THETA was not previously known. Since rabbit aorta contains 15-LO and synthesizes 15(S)-HPETE at 94% optical purity (21, 26), the THETA must contain a 15(S)-hydroxyl. However, configurations of the 11- and 12-hydroxyls were not known. Since the aorta does not produce an adequate mass of 11,12,15-THETA for analytic determination of the stereochemical structure, we compared chromatographic migration of the biological 11,12,15-THETA with that of eight synthetic stereoisomers (Fig. 1). Of these isomers, only 11(R),12(S),15(S)-trihydroxyeicosa-5(Z),8(Z),13(E)-trienoic acid comigrated with the biological 11,12,15-THETA on RP-HPLC, NP-HPLC, and GC, relaxed the rabbit aorta, and activated SKCa channels. These studies suggest that 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA is the vasodilator produced by the rabbit aortic endothelium.
Although previous studies indicate that biological 11,12,15-THETA relaxes the rabbit aorta and activates SKCa channels (3, 12), the exact concentration of the biosynthesized THETA could not be determined. Thus it was important to determine the potency of the synthetic 11(R),12(S),15(S), 5(Z),8(Z),13(E)-THETA. These studies indicate that 10–7–10–4 M 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA relaxed the preconstricted aorta in a concentration-related manner. Maximal relaxation was 69%. High 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA concentrations (
10–6 M) were required to cause relaxation. THETAs share lipophilic properties of other fatty acids: they are poorly soluble in aqueous buffers, stick to the bath surfaces, and form micelle aggregates. Therefore, free THETA concentrations available for the activation of relaxation are less than the added concentrations.
Nothing is known about the metabolism of 11,12,15-THETA by vascular cells. Since there are strict structural and stereochemical requirements for vascular activity, metabolism of 11,12,15-THETA would result in a loss of activity. Many eicosanoids and prostanoids with a 15-hydroxyl group are inactivated by 15-hydroxyprostaglandin dehydrogenase, which converts the hydroxyl to a ketone, and subsequent reduction of the
13,14-olefin by a reductase (1, 14). β- and
-oxidation are other inactivation pathways. It is not known whether 11,12,15-THETA is a substrate for these enzymes.
In rabbit arteries, 11,12,15-THETA acts as an EDHF (3, 12). Relaxations to the biological 11,12,15-THETA are blocked by high extracellular K+ and apamin, indicating an action on KCa channels. Similar to the biological 11,12,15-THETA, 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA activated SKCa channels, which will cause membrane hyperpolarization and vascular relaxation. Relaxations to 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA were inhibited by the SKCa channel blocker apamin. 11(R),12(S),15(S),5(Z),8(Z),13(E)-THETA also increased aortic smooth muscle cell outward K+ current, which was blocked by apamin. Other 11,12,15(S)-THETA isomers did not display this vascular activity. Interestingly, 10–4 M 11(R),12(R),15(S),5(Z),8(Z),13(E)-THETA caused a small but significant increase in outward K+ current but caused vascular constriction. The reason for this discrepancy is not known, but it suggests that the mechanism of the vascular constriction is unrelated to K+ channel activation.
These studies indicate that an exact stereochemical configuration of 11,12,15-THETA is needed for biological activity. The configuration of the hydroxyls and olefin between carbons 13 and 14 is critical for full activity. All THETAs with the cis-
13,14-olefin [13(Z) series] were inactive. Of the 11,12,15-THETAs with the trans-
13,14-olefin [13(E) series], 11(R),12(S),15(S)-THETA was a potent agonist, whereas the other stereoisomers were weak agonists or were without activity. The requirements for a specific structure and stereochemical configuration suggest that a specific binding site or receptor is involved in mediating the KCa channel activation and vascular relaxations. There are examples of membrane receptors for trihydroxylated AA metabolites. Lipoxin A4, a trihydroxy metabolite of AA, also has strict structural requirements for activity, and its membrane receptor has been identified (10, 13). Trioxilin A3 and B3 are THETAs formed by the 12-LO pathway (18, 19). Ichthyin and NIPA1 are thought to be membrane receptors for these ligands (15).
In summary, our studies strongly suggest that 11(R),12(S),15(S)-trihydroxyeicosa-5(Z),8(Z),13(E)-trienoic acid is the vasodilator produced by rabbit aorta that mediates relaxations to acetylcholine and AA. This conclusion was based on the comigration of this stereoisomer with the biological 11,12,15-THETA in three chromatographic systems and similar vascular biological activities. The strict structural requirements for vascular biological activity suggest that a specific binding site or receptor is required.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
and inhibits tumor necrosis factor-
-induced IL-8 release. J Exp Med 187: 1285–1294, 1998.This article has been cited by other articles:
![]() |
Y. Chawengsub, K. M. Gauthier, K. Nithipatikom, B. D. Hammock, J. R. Falck, D. Narsimhaswamy, and W. B. Campbell Identification of 13-Hydroxy-14,15-epoxyeicosatrienoic Acid as an Acid-stable Endothelium-derived Hyperpolarizing Factor in Rabbit Arteries J. Biol. Chem., November 6, 2009; 284(45): 31280 - 31290. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chawengsub, K. M. Gauthier, and W. B. Campbell Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H495 - H507. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chawengsub, N. T. Aggarwal, K. Nithipatikom, K. M. Gauthier, S. Anjaiah, B. D. Hammock, J. R. Falck, and W. B. Campbell Identification of 15-hydroxy-11,12-epoxyeicosatrienoic acid as a vasoactive 15-lipoxygenase metabolite in rabbit aorta Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1348 - H1356. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |